We use medical-grade, high-quality ingredients tailored to your needs
The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes 14 metabolic pathways and 150+ genetic insights, including variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body responds to GLP-1 therapy and processes carbohydrates like those in bananas
Glutathione is a powerful antioxidant that helps reduce the appearance of dark spots and hyperpigmentation while su
Highlights from Novo Nordisks presentation include (see Figure 1): Analysis of the three components in MACE: Semaglutide 2.4 mg reduced the risk of Non-fatal myocardial infarction by 28% Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints: Semaglutide 2.4 mg reduced the risk of Composite heart failure events, comprising cardiovascular death, urgent heart failure visits and hospitalisations, by 18% Death from any cause by 19% Note: Since the result on cardiovascular death, the first confirmatory secondary endpoint, was not statistically significant over the length of the trial, the remaining secondary confirmatory endpoints were not tested for superiority due to hierarchical testing
These combination approaches raise important questions about receptor saturation, cumulative side effects, and whether dual agonism produces additive or synergistic outcomes
Backed by Motorsport Australia
